The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Mutant (MT) KRAS codon 12 and 13 alleles in patients (pts) with metastatic colorectal cancer (mCRC): Assessment as prognostic and predictive biomarkers of response to panitumumab (pmab).
Marc Peeters
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
Other Remuneration - Amgen
Jean-Yves Douillard
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Eric Van Cutsem
Research Funding - Amgen
Salvatore Siena
Consultant or Advisory Role - Amgen; AstraZeneca; Merck Serono; Roche
Kathy Zhang
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Richard Thomas Williams
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Jeffrey S. Wiezorek
Employment or Leadership Position - Amgen
Stock Ownership - Amgen